Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis
Brian S Kim1, Shawn G Kwatra2,3, Gil Yosipovitch4
1Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background:
Prurigo nodularis (PN) is a complex to manage heterogenous disease with limited available treatments. Patients with PN are usually older, with multiple comorbidities adding to the complexity of their care, frequently having failed to control symptoms with other treatments.
Objective:
The objective of this analysis was to evaluate the efficacy of dupilumab across various patient subgroups based on their comorbidities, previous use of other medication or demographic characteristics.
Methods:
In the PRIME and PRIME2 studies 311 adult patients with PN were randomized to either dupilumab (300 mg every 2 weeks [q2w]) or matching placebo for 24 weeks. Data from both studies were pooled, and the proportion of patients achieving improvement in itch (measured by Worst-Itch Numerical Rating Scale [WI-NRS] ≥ 4) and lesions (measured by Investigator's Global Assessment [IGA] PN-S [PN-Stage] 0 or 1) or the combination of both at 24 weeks was analyzed according to subgroups stratified by age, gender, body mass index (BMI), presence of comorbidities, and prior treatment use.
Results:
Dupilumab treatment resulted in itch and lesion improvements at Week 24 compared with placebo in all subgroups studied, with statistical superiority demonstrated in most subgroups tested in this analysis.
Conclusion:
Targeting type 2 inflammation with dupilumab was beneficial independent of age, gender, comorbidities and prior medication.
